CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that updated clinical data from the pivotal PACE trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, June 1-5, 2012.
